Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emeline Colomba

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancerJuan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
Clinical Genitourinary Cancer|August 17, 2022
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II StudyElie Rassy, Cécile Dalban, Emeline Colomba, et al.
Journal for Immunotherapy of Cancer|July 27, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockersLaetitia Nebot-Bral, Antoine Hollebecque, Andrey A Yurchenko, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomesAurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2024
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa, et al.
BMC Cancer|November 4, 2025
Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohortJohan Rose-Dite-Modestine, Alexis Vallard, Jean-Samuel Loger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinomaLucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.
Journal for Immunotherapy of Cancer|July 2, 2024
Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancerJuan Francisco Grau Bejar, Elisa Yaniz Galende, Qinghe Zeng, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
Clinical Genitourinary Cancer|August 17, 2022
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II StudyElie Rassy, Cécile Dalban, Emeline Colomba, et al.
Journal for Immunotherapy of Cancer|July 27, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockersLaetitia Nebot-Bral, Antoine Hollebecque, Andrey A Yurchenko, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomesAurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2024
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa, et al.
BMC Cancer|November 4, 2025
Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohortJohan Rose-Dite-Modestine, Alexis Vallard, Jean-Samuel Loger, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinomaLucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, et al.
Pageof 7